Other · developed by Shattuck Labs
SL-325 is an agent administered intravenously.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07753850 | Phase 2 | Crohn's Disease | Recruiting | STTK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Crohn's Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the STTK page.
See STTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STTK catalysts and pipeline →